SCHEMBL1890748

SCHEMBL1890748

CC(C)n1ncc2cc(Br)c(=O)n(C)c21

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE1C Q14123 1/20 0.34
KAT2B Q92831 1/20 0.32
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
XBP1 P17861 1/20 0.30
HTT P42858 1/20 0.30
RAB9A P51151 1/20 0.30
PAX8 Q06710 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
AURKA O14965 1/20 0.30
CDK1 P06493 1/20 0.30
AURKB Q96GD4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3638431 0.68 MAPK14 (0.51) PDE1CNPC1ALDH1A1LMNAGAA
SCHEMBL9726416 0.67 ALDH1A1 (0.46) PDE1CKAT2BKDM4ENPC1ALDH1A1
SCHEMBL22939501 0.65 KDM4E (0.42) KDM4E
SCHEMBL29861795 0.65 CYP1A2 (0.46) ALDH1A1
SCHEMBL20155367 0.62 CREBBP (0.34) PDE1CKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL28920149 0.62 GAA (0.34) KDM4EGAAMAPTAURKA
SCHEMBL22939496 0.62 ALDH1A1 (0.41) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL31532052 0.62 FGFR1 (0.60)
SCHEMBL19698900 0.61 ADORA2B (0.34) PDE1CKAT2BKDM4EALDH1A1MAPT
SCHEMBL17300645 0.61 KDM4E (0.38) PDE1CKDM4EALDH1A1SMN1; SMN2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8435987-B2 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof AMGEN INC. (US) 2013-05-07 US disclosed
US-8435987-B2 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof AMGEN INC. (US) 2013-05-07 US disclosed
US-8435987-B2 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof AMGEN INC. (US) 2013-05-07 US disclosed
US-20110294805-A1 PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF AMGEN INC. (US) 2011-12-01 US disclosed
US-20110294805-A1 PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF AMGEN INC. (US) 2011-12-01 US disclosed
US-20110294805-A1 PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF AMGEN INC. (US) 2011-12-01 US disclosed
US-8022085-B2 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof AMGEN INC. (US) 2011-09-20 US disclosed
US-8022085-B2 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof AMGEN INC. (US) 2011-09-20 US disclosed
US-8022085-B2 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof AMGEN INC. (US) 2011-09-20 US disclosed
US-20110105498-A1 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof AMGEN INC. (US) 2011-05-05 US disclosed
US-7846944-B2 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2010-12-07 US disclosed
US-7846944-B2 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2010-12-07 US disclosed
EP-2152704-A1 PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE Amgen, Inc (US) 2010-02-17 EP disclosed
EP-2152706-A1 PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE Amgen Inc. (US) 2010-02-17 EP disclosed
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2009-01-08 US disclosed
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2009-01-08 US disclosed
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2009-01-08 US disclosed
WO-2008136948-A1 PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE AMGEN INC. (US) 2008-11-13 WO disclosed
WO-2008136948-A1 PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE AMGEN INC. (US) 2008-11-13 WO disclosed
WO-2008137176-A1 PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294805-A1 PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF MAPK1, MAP4K2, MAP3K1 PDE1C 976/4885KAT2B 2369/4885KDM4E 3644/4885
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof MAPK1, MAP3K1, MAP4K2 PDE1C 1000/4885KAT2B 3250/4885KDM4E 3878/4885
US-20110105498-A1 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof MAPK1, MAP4K2, MAP3K1 PDE1C 976/4885KAT2B 2369/4885KDM4E 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.